Evidence map›Paper›PMID 42505234›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Early Adherence to Immunomodulators in Multiple Myeloma: Retrospective Observations from a Safety-Net Hospital.

Onyebuchi Ononogbu, Sydney Mohr, Javeria Khalid, Alyssa Glass, Jane Emovon, Hilary Ma, Yaser Alkhatib, Amit Correa

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Onyebuchi OnonogbuDepartment of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX 77204, USA.ORCID 0000-0002-5662-4686
Sydney MohrDepartment of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Javeria KhalidDepartment of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX 77204, USA.ORCID 0000-0002-4850-9215
Alyssa GlassDepartment of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Jane EmovonDepartment of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Hilary MaDepartment of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yaser AlkhatibDepartment of Medical Oncology, Cleveland Clinic Abu Dhabi, Abu Dhabi 112412, United Arab Emirates.ORCID 0000-0002-1208-9503
Amit CorreaLyndon B. Johonson Outpatient Hematology, Harris Health System, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunologic FactorsImmunomodulating AgentsMultiple MyelomaAgedFemaleHumansLenalidomideMaleMiddle AgedRetrospective StudiesSafety-net ProvidersThalidomideImmunologic FactorsImmunomodulating AgentsLenalidomideThalidomidehealth disparitiesimmunomodulatorslenalidomidemedication adherencemultiple myelomaPatient Medication Assistance Programpomalidomideproportion of days coveredREMSsafety-net hospital

Identifiers

PMID42505234
PMCPMC13408047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.